In 2020, the COVID-19 outbreak led to a sudden slowdown in consumer lending in Denmark. This was due to the immediate economic impact of the pandemic, which significantly reduced inclination among consumers to take on debt. Income losses and a high level of uncertainty over economic prospects as a result of the pandemic swiftly reduced demand for consumer lending.

Also Read:…

After steady growth throughout the review period, consumer lending in Canada is expected to record its first decline since 2011 in 2020 as a direct result of the financial and economic impacts of the Coronavirus (COVID-19) epidemic. Consumer credit will drive the decline, with auto lending likely to witness a steep, double-digit fall over the course of the year. Auto sales took a significant hit early in year, with some estimates showing a decline in sales of around 50% in March alone. Many…

Consumer health is expected to see slightly higher current value growth in 2020 than was seen in 2019, with COVID-19 expected to be one of the main factors dictating growth in Uruguay. While the COVID-19 outbreak in Uruguay had little impact in terms of infections and deaths due to the country’s good healthcare system, locals’ concern about their health remained high. The government did not impose very strict restrictions, instead suggesting a short quarantine from mid-March through the end…

The fast-spreading COVID-19 virus has dampened economic prospects for 2020. Consumer confidence has been directly hit in Q2 as a result of the first case of COVID-19 being seen at the end of Q1 (11 March), leading to consumers increasingly opting for cheaper Consumer Health brands and generics. As well as rises in raw material prices, there have been disruptions in logistics services for transporting the raw materials from abroad given movement restrictions in place to help slow the virus…

The outbreak of COVID-19 is not expected to increase growth in 2020, with value growth of 2% predicted for the year, compared to value growth of 4% recorded in 2019. Unlike other countries, Sweden did not go into a full lockdown during Q1 and Q2, and this had some impact on the level of stockpiling that took place, which was mainly seen in adult analgesics and cough remedies.

Also Read:…

The COVID-19 pandemic is not having the same drastic impact on consumer health as seen with other industries in 2020. The industry has been allowed to continue its operations because it produces and sells necessity products, some of which have increased in demand in response to the outbreak of the virus. Likewise, the key retail distributors responsible for sales in Guatemala have been permitted to remain open throughout lockdown and the ongoing restrictions. Despite having authorisation…

Overall, consumer health is expected to perform well due to the increased demand for products as a result of COVID-19. Paediatric consumer health is expected to register the highest value growth, followed by vitamins and analgesics and cough, cold remedies. However, the value growth is not expected across all product areas. In fact, the largest product area in terms of value sales, weight management and wellbeing, is expected to register a double-digit decline in value sales. Sales of sports…

Charge cards had not established a presence in the Japanese market by the end of the review period. The potential development of this card type is hindered by the fact that consumers perceive credit cards to offer greater convenience and flexibility. Moreover, credit cards are still emerging strongly and taking transaction share from cash, providing little incentive for the introduction of charge cards. With credit cards expected to continue to grow, card issuers are unlikely to shift their…

COVID-19 caused a spike in demand for analgesics, meaning analgesics is expected to see an even stronger increase in retail current value growth in 2020 when compared to 2019. This is due to the fact that the government in Uruguay initially recommended the use of acetaminophen, rather than ibuprofen in terms of treatment of symptoms for COVID-19. As a result, both adult and paediatric acetaminophen experienced solid growth in both current value and retail volume terms in 2020. In fact,…

Due to initial concern that anti-inflammatory drugs such as ibuprofen and aspirin may worsen COVID-19 symptoms, in 2020 the World Health Organization initially recommended against the use of these anti-inflammatory drugs. However, it changed its position several days later and no longer recommends against ibuprofen or other anti-inflammatory drugs, including aspirin. Therefore, increases in aspirin sales have been evident since Q2, as more Turks look to counter the effects of COVID-19 such…

Acetaminophen and combination products drive the performance of this category, accounting for the greatest proportion of sales. Consumers prefer early treatment when they feel the onset of a fever or body aches, and these products are considered safe and convenient. Consumers are aware of the consequences of going to a hospital, including lack of public transportation due to COVID-19 restrictions, and the possibility of contracting the virus when outside the home, and so in 2020 increasingly…

The outbreak of COVID-19 in Sweden is set to boost value growth in analgesics in 2020, with a predicted growth of 4% for the year, compared to the recorded growth of 2% for 2019. A spike in sales was seen during March and April, when consumers stockpiled analgesics, fearing that the virus would lead to supply shortages, while consumers wanted to ensure they would have enough for personal use if they contracted the virus. Many consumers were also worried that restrictions on the availability…

After seeing strong growth in 2019, analgesics is expected to see an even stronger performance in 2020 overall. The outbreak of COVID-19 has led to a surge in demand for analgesics in Guatemala that is set to continue throughout the rest of the year. Demand has been generated by both consumers infected with the virus and thus turning to OTC remedies to relieve symptoms, and consumers afraid of a future shortage and therefore stockpiling. India, which is the largest supplier of both…

After seeing solid retail current value growth in 2019, analgesics is expected to see an even stronger increase in 2020, with current value growth expected to double. The COVID-19 pandemic is set to create a spike in demand for analgesics, with higher sales related to consumers stockpiling, and less to the treatment of ailments. In fact, analgesics were amongst the most purchased items in the early stages of the virus in the country, in February and early March, due to consumers’ belief that…

Wound care is expected to see a slowdown in its current value growth rate in 2020, mainly due to the COVID-19 pandemic. In response to the virus, in the first half of the year the government implemented social isolation guidelines to limit its spread, closing retail outlets, gyms and schools, for instance, and encouraging people to remain at home as much as possible. Less time spent outside the home meant less chance of injuries, hampering the growth of wound care in 2020. Nevertheless, the…

Wound care was strongly affected by COVID-19 and will see a decrease in retail value in 2020. During quarantine, consumers remained at home and avoided outside activities, thus limiting the potential for injuries requiring wound care products. Planned operations in hospitals were also cancelled during the lockdown period, so post-operation care using wound care products were no longer needed.

Also Read:…

Wound care is seeing small continued growth in 2020, with gauze, tape and other wound care continuing to be the largest sub-category and show the strongest growth. The affordable prices of such products and their wide availability means that many consumers purchase their own wound care products as opposed to attending hospitals to have their wounds treated. This is particularly so in the time of COVID-19, with fewer medical appointments available and patients more reticent about attending a…

Compared with the rest of the review period, wound care is expected to see a slight slowdown in growth in 2020. One of the main factors ensuring growth in the review period was consumer lifestyles, with the category seeing growth due to more consumers participating in sports and outdoor activities. However, with the lockdown due to COVID-19 in the first half of 2020 there was less chance to go to the gym, practice sport or participate in outdoor activities. This led to less chance of…

Already modest for most of the review period, growth in value sales of wound care slowed significantly during 2020, largely as a result of the impact of COVID-19. As wound care is a fairly low priority for most consumers, many have reduced their spending on these products during a time of heightened economic uncertainty. However, some support for wound care sales was provided by the ending of COVID-19 restrictions on movement, which spurred a wave of outdoor physical activity that exposed…

COVID-19 and its far-reaching effects will hit wound care sales hard in 2020. Although some households stocked up on gauze, tape and other wound care at the start of the COVID-19 pandemic, making it the only category to post positive growth in 2020, this growth was marginal and consumers are likely to use up excess reserves before buying more, dampening sales in the future. With Slovaks forced to spend more time indoors due to lockdown restrictions, consumers avoided the usual bumps, scrapes…